Grant: Collaborative Health Research Projects
University of Ottawa
$252,300.00
Development of small molecule viral sensitizers to boost vaccine manufacturing
FY 2013-14
Summary
Virus-based vaccines are society's most successful pharmaceuticals for the prevention of deadly human diseases. Diseases like smallpox, polio, measles, mumps and rubella have been essentially eliminated from human populations where widespread vaccination programs have been implemented. One characteristic common to all vaccines is that they must be engineered or selected to have attenuated growth characteristics in order to ensure an acceptable safety profile in humans. While attenuation of the ability of a viral vaccine to block cellular innate immune responses creates an extremely safe product, it also impairs the growth of the virus in cell lines used for industrial manufacturing, decreasing the timely delivery of vaccines. The acute vaccine supply shortages experienced during the 2009 H1N1 vaccination program underscore the need fortimely manufacturing of large amounts of vaccine. Our Solution: We have discovered that it is possible to use small molecules to target and inhibit the same cellular pathways that virus virulence genes target. Our lead compounds, coined virus sensitizers or VSes, can significantly enhance the growth of viral therapeutics, in some cases by over 1000 fold. A key advantage of using small molecules to boost vaccine production is that neither the virus-based vaccine nor the manufacturingcell line need be genetically modified. This minimizes the regulatory hurdles for implementing our technology to improving vaccine manufacturing, enabling faster translation to improved health outcomes for Canadians. To translate our technology to an industrial setting, several key issues need to be addressed. These include (1) Optimization of VSe activity and physiocochemical properties (2) Assessment of VSe toxicology and end-product bioequivalence (3) Validation of VSe impact in small scale manufacturing applications, which will be done in collaboration with our technology end user Jennerex Biotherapeutics, and (4) Identification of VSe molecular targets. This proposal describes our multi-disciplinary approach to address these key questions.
Program
Collaborative Health Research Projects
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
414215-2012
Name nom
Boddy, Christopher
Department département
Chemistry
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2012
Award amount
252300
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
2 & 3
Nb partie
3
Application title
Development of small molecule viral sensitizers to boost vaccine manufacturing
Keyword
NSERC
Application summary
Virus-based vaccines are society's most successful pharmaceuticals for the prevention of deadly human diseases. Diseases like smallpox, polio, measles, mumps and rubella have been essentially eliminated from human populations where widespread vaccination programs have been implemented. One characteristic common to all vaccines is that they must be engineered or selected to have attenuated growth characteristics in order to ensure an acceptable safety profile in humans. While attenuation of the ability of a viral vaccine to block cellular innate immune responses creates an extremely safe product, it also impairs the growth of the virus in cell lines used for industrial manufacturing, decreasing the timely delivery of vaccines. The acute vaccine supply shortages experienced during the 2009 H1N1 vaccination program underscore the need fortimely manufacturing of large amounts of vaccine. Our Solution: We have discovered that it is possible to use small molecules to target and inhibit the same cellular pathways that virus virulence genes target. Our lead compounds, coined virus sensitizers or VSes, can significantly enhance the growth of viral therapeutics, in some cases by over 1000 fold. A key advantage of using small molecules to boost vaccine production is that neither the virus-based vaccine nor the manufacturingcell line need be genetically modified. This minimizes the regulatory hurdles for implementing our technology to improving vaccine manufacturing, enabling faster translation to improved health outcomes for Canadians. To translate our technology to an industrial setting, several key issues need to be addressed. These include (1) Optimization of VSe activity and physiocochemical properties (2) Assessment of VSe toxicology and end-product bioequivalence (3) Validation of VSe impact in small scale manufacturing applications, which will be done in collaboration with our technology end user Jennerex Biotherapeutics, and (4) Identification of VSe molecular targets. This proposal describes our multi-disciplinary approach to address these key questions.